HRP20021039B1 - Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja - Google Patents

Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja

Info

Publication number
HRP20021039B1
HRP20021039B1 HR20021039A HRP20021039A HRP20021039B1 HR P20021039 B1 HRP20021039 B1 HR P20021039B1 HR 20021039 A HR20021039 A HR 20021039A HR P20021039 A HRP20021039 A HR P20021039A HR P20021039 B1 HRP20021039 B1 HR P20021039B1
Authority
HR
Croatia
Prior art keywords
optionally substituted
halogen
independently selected
ora
heteroaryl
Prior art date
Application number
HR20021039A
Other languages
English (en)
Croatian (hr)
Inventor
Labelle Marc
Sturino Claudio
Roy Bruno
Berthelette Carl
Boyd Michael
Lachance Nicolas
Scheigetz John
Original Assignee
Merck Frosst Canada & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada & Co. filed Critical Merck Frosst Canada & Co.
Publication of HRP20021039A2 publication Critical patent/HRP20021039A2/hr
Publication of HRP20021039B1 publication Critical patent/HRP20021039B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/38—TPC being performed in particular situations
    • H04W52/46—TPC being performed in particular situations in multi-hop networks, e.g. wireless relay networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B17/00—Monitoring; Testing
    • H04B17/30—Monitoring; Testing of propagation channels
    • H04B17/309—Measuring or estimating channel quality parameters
    • H04B17/318—Received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/02—Access restriction performed under specific conditions
    • H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/06—TPC algorithms
    • H04W52/14—Separate analysis of uplink or downlink
    • H04W52/146—Uplink power control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non-transmission
    • H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non-transmission taking into account the usage mode, e.g. hands-free, data transmission or telephone
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/20—Selecting an access point
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Computer Security & Cryptography (AREA)
  • Quality & Reliability (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Materials For Photolithography (AREA)
HR20021039A 2000-07-25 2001-07-23 Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja HRP20021039B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068300P 2000-07-25 2000-07-25
PCT/CA2001/001069 WO2002008186A2 (en) 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Publications (2)

Publication Number Publication Date
HRP20021039A2 HRP20021039A2 (en) 2004-10-31
HRP20021039B1 true HRP20021039B1 (hr) 2011-03-31

Family

ID=22824535

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20021039A HRP20021039B1 (hr) 2000-07-25 2001-07-23 Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja

Country Status (33)

Country Link
US (1) US6410583B1 (cs)
EP (1) EP1305286B1 (cs)
JP (1) JP4119745B2 (cs)
KR (1) KR100746814B1 (cs)
CN (1) CN1214007C (cs)
AT (1) ATE284388T1 (cs)
AU (2) AU7743001A (cs)
BG (1) BG66084B1 (cs)
BR (1) BR0112756A (cs)
CA (1) CA2416867C (cs)
CZ (1) CZ2003236A3 (cs)
DE (1) DE60107687T2 (cs)
DK (1) DK1305286T3 (cs)
DZ (1) DZ3402A1 (cs)
EA (1) EA006765B1 (cs)
EC (1) ECSP034428A (cs)
EE (1) EE05287B1 (cs)
ES (1) ES2231526T3 (cs)
GE (1) GEP20053595B (cs)
HR (1) HRP20021039B1 (cs)
HU (1) HUP0301745A3 (cs)
IL (2) IL153406A0 (cs)
IS (1) IS2170B (cs)
MX (1) MXPA03000710A (cs)
NO (1) NO325011B1 (cs)
NZ (1) NZ523106A (cs)
PL (1) PL207342B1 (cs)
PT (1) PT1305286E (cs)
RS (1) RS50491B (cs)
SK (1) SK287507B6 (cs)
UA (1) UA73787C2 (cs)
WO (1) WO2002008186A2 (cs)
ZA (1) ZA200300554B (cs)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
WO2000010531A1 (en) 1998-08-19 2000-03-02 Rtp Pharma Inc. Injectable aqueous dispersions of propofol
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
AR031195A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US6784172B2 (en) 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AU2002239463A1 (en) * 2000-11-03 2002-06-03 Wyeth Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
AR031197A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US20070054951A1 (en) * 2003-05-20 2007-03-08 Lianhai Li Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
AU2004247285A1 (en) * 2003-06-12 2004-12-23 Merck Frosst Canada Ltd Cycloalkanepyrrolopyridines as DP receptor antagonists
US20080153817A1 (en) * 2003-08-07 2008-06-26 Dirk Beher Treatment for Alzheimer's Disease and Related Conditions
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2006008118A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006113150A1 (en) * 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US7902177B2 (en) 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
BRPI0916812B8 (pt) 2008-07-23 2022-10-18 Arena Pharm Inc Derivados do ácido 1,2,3,4-tetra-hidrociclopenta[b]indol-3-il)acético substituído úteis no tratamento de distúrbios autoimunes e inflamatórios, seu uso, composição farmacêutica que os compreende e processo de preparação
PT2342205T (pt) 2008-08-27 2016-07-28 Arena Pharm Inc Derivados de ácido tricíclico substituído como agonistas de recetor s1p1 úteis no tratamento de distúrbios autoimunes e inflamatórios
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
US8685999B2 (en) 2008-09-25 2014-04-01 Merck Sharp & Dohme Corp. Beta carboline sulphonylurea derivatives as EP4 receptor antagonists
WO2010081823A1 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as otoprotective agent
WO2011051151A1 (de) 2009-10-26 2011-05-05 Bayer Cropscience Ag Neue feste form von 4-[[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5h)-on
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
CN102884064B (zh) 2010-03-03 2016-01-13 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
ES2991300T3 (es) 2015-02-13 2024-12-03 Inserm Institut Nat De La Sante Et De Larecherche Medicale Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
AU2018222747A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
EP3682250A4 (en) 2017-09-13 2021-03-03 Progenity, Inc. PRE-ECAMPSY BIOMARKERS AND ASSOCIATED SYSTEMS AND PROCESSES
US11279656B2 (en) * 2017-10-27 2022-03-22 Applied Materials, Inc. Nanopowders, nanoceramic materials and methods of making and use thereof
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN115260173B (zh) * 2021-04-30 2024-08-30 厦门宝太生物科技股份有限公司 环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) * 2023-07-10 2023-10-10 青岛科技大学 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
EP0234708A1 (en) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787444A (fr) 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
EA000987B1 (ru) * 1995-06-21 2000-08-28 Сионоги Энд Ко., Лтд. Бициклические аминопроизводные и содержащие их антагонисты pgd2
DK0944614T3 (da) * 1996-12-13 2003-01-13 Shionogi & Co Benzothiophencarboxamidderivater og PGD2-antagonister, der omfatter dem
ATE295183T1 (de) * 1998-06-03 2005-05-15 Shionogi & Co Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
EP0234708A1 (en) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Also Published As

Publication number Publication date
NO325011B1 (no) 2008-01-14
ECSP034428A (es) 2003-03-10
CN1214007C (zh) 2005-08-10
CZ2003236A3 (cs) 2003-05-14
IS2170B (is) 2006-11-15
YU97902A (sh) 2006-05-25
JP2004504380A (ja) 2004-02-12
HUP0301745A2 (hu) 2003-09-29
NZ523106A (en) 2005-01-28
PT1305286E (pt) 2005-04-29
IL153406A0 (en) 2003-07-06
CA2416867C (en) 2008-03-25
GEP20053595B (en) 2005-08-10
SK287507B6 (sk) 2010-12-07
HRP20021039A2 (en) 2004-10-31
AU2001277430B2 (en) 2006-05-25
JP4119745B2 (ja) 2008-07-16
EE200300033A (et) 2004-10-15
ES2231526T3 (es) 2005-05-16
BG66084B1 (bg) 2011-03-31
HK1058934A1 (en) 2004-06-11
EA006765B1 (ru) 2006-04-28
HUP0301745A3 (en) 2010-03-29
CN1443165A (zh) 2003-09-17
UA73787C2 (en) 2005-09-15
CA2416867A1 (en) 2002-01-31
ZA200300554B (en) 2004-04-23
EA200300171A1 (ru) 2003-06-26
NO20030374L (no) 2003-01-24
MXPA03000710A (es) 2003-06-04
ATE284388T1 (de) 2004-12-15
IL153406A (en) 2008-03-20
WO2002008186A2 (en) 2002-01-31
EP1305286B1 (en) 2004-12-08
IS6655A (is) 2002-12-12
PL363168A1 (en) 2004-11-15
BR0112756A (pt) 2003-06-24
KR100746814B1 (ko) 2007-08-06
DZ3402A1 (fr) 2002-01-31
EP1305286A2 (en) 2003-05-02
US6410583B1 (en) 2002-06-25
AU7743001A (en) 2002-02-05
DE60107687T2 (de) 2005-12-01
NO20030374D0 (no) 2003-01-24
RS50491B (sr) 2010-03-02
EE05287B1 (et) 2010-04-15
DK1305286T3 (da) 2005-03-14
KR20030024810A (ko) 2003-03-26
SK932003A3 (en) 2003-06-03
DE60107687D1 (de) 2005-01-13
PL207342B1 (pl) 2010-12-31
WO2002008186A3 (en) 2002-03-21
BG107438A (bg) 2003-09-30

Similar Documents

Publication Publication Date Title
HRP20021039B1 (hr) Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja
EE05126B1 (et) Trifenlalkeeni derivaadid ja nende kasutamine selektiivsete ”strogeeniretseptorite modulaatoritena
DE69501947D1 (de) SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
YU68896A (sh) Jedinjenja hinolina i nihazolina od koristi u terapiji
CY1106497T1 (el) Νεες αρυλοξυ-αλκυλ-διαλκυλαμινες
YU165391A (sh) Derivati indola
YU48855B (sh) Heterociklična jedinjenja i njihovi derivati koji su modifikatori dejstva 5-hidroksi-triptamina i postupak njihovog dobijanja
HRP20040977B1 (hr) Derivati n-[fenil(piperidin-2-il)metil]benzamida,postupak njihovog pripravljanja i primjena istih u terapiji
CO5280046A1 (es) Agonistas alfa 7 y sus composiciones farmaceuticas
GB9602166D0 (en) Aminoheterocyclic derivatives
DK0673375T3 (da) Kondenserede benzoforbindelser
HRP20070498T3 (en) Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9900584A2 (hu) Új benzoil-guanidin-származékok, eljárás előállításukra és gyógyszerkészítmények előállításában való felhasználásuk
ES8700856A1 (es) Un procedimiento para la preparacion de compuestos de 1, 4-dihidropiridina
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
DK152212C (da) Analogifremgangsmaade til fremstilling af 2-substituerede 4-hydroxy-3-quinolincarboxylsyrederivater
HRP20000878B1 (hr) Kemijska sinteza derivata morfolina
CO4920251A1 (es) Compuestos hexahidro 1 h. -pirrolizina 7 a. -heterociclico- substituidos utiles en el control de la transmision sinaptica quimica
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
MEP21808A (en) Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
DK50089A (da) 2-oe(4-piperidinyl)methylaa-1,2,3,4-tetrahydroisoquinolin-derivater, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
YU47605B (sh) Postupak za dobijanje supstituisanih derivata stirena
ATE365722T1 (de) 2,4,6-tris(4&#39;aminobenzaldineopentylmalonat)-s- triazin, dieser enthaltenden sonnenschutzzusammensetzungen und dessen verwendungen
YU44592A (sh) Derivati 4-aril-3-(heteroarilkarbamido) hinolina
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130716

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20140723